The new hopes of CETP inhibitors

被引:0
|
作者
Farnier, M. [1 ]
机构
[1] Point Med, Dijon, France
来源
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2012年 / 16卷 / 04期
关键词
HIGH-RISK; CORONARY; MASS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:98 / 100
页数:3
相关论文
共 50 条
  • [31] CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet
    Zhu, Lin
    Luu, Thao
    Emfinger, Christopher H.
    Parks, Bryan A.
    Shi, Jeanne
    Trefts, Elijah
    Zeng, Fenghua
    Kuklenyik, Zsuzsanna
    Harris, Raymond C.
    Wasserman, David H.
    Fazio, Sergio
    Stafford, John M.
    DIABETES, 2018, 67 (12) : 2494 - 2506
  • [32] Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
    Blauw, Lisanne L.
    Noordam, Raymond
    Soidinsalo, Sebastian
    Blauw, C. Alexander
    Li-Gao, Ruifang
    de Mutsert, Renee
    Berbee, Jimmy F. P.
    Wang, Yanan
    van Heemst, Diana
    Rosendaal, Frits R.
    Jukema, J. Wouter
    Mook-Kanamori, Dennis O.
    Wurtz, Peter
    van Dijk, Ko Willems
    Rensen, Patrick C. N.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 (03) : 422 - 431
  • [33] Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
    Hu, Wenhui
    Feng, Han
    Liu, Ying
    Xu, Xiaoshuang
    Zhou, Ping
    Sun, Zhonghua
    Tao, Xinyu
    Yang, Jiahui
    Wu, Jun
    Qu, Chen
    Liu, Zhengxia
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [34] Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial
    Brinton, Eliot A.
    Kher, Uma
    Shah, Sukrut
    Cannon, Christopher P.
    Davidson, Michael
    Gotto, Antonio M.
    Ashraf, Tanya B.
    Sisk, Christine McCrary
    Dansky, Hayes
    Mitchel, Yale
    Barter, Philip
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (01) : 65 - 71
  • [35] CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population
    Wang, Jun
    Wang, Li Jun
    Zhong, Yong
    Gu, Ping
    Shao, Jia Qing
    Jiang, Shi Sen
    Gong, Jian Bin
    LIPIDS IN HEALTH AND DISEASE, 2013, 12
  • [36] Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes
    Shalhout, Sophia Z.
    Kaufman, Howard L.
    Emerick, Kevin S.
    Miller, David M.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2211 - 2220
  • [37] On- and Off-Target Pharmacology of Torcetrapib Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors
    Johns, Douglas G.
    Duffy, Joseph
    Fisher, Timothy
    Hubbard, Brian K.
    Forrest, Michael J.
    DRUGS, 2012, 72 (04) : 491 - 507
  • [38] New JAK2 inhibitors for myeloproliferative neoplasms
    Quintas-Cardama, Alfonso
    Verstovsek, Srdan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) : 961 - 972
  • [39] Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions
    Qureischie, H.
    Heun, R.
    Popp, J.
    Jessen, F.
    Maier, W.
    Schmitz, S.
    Hentschel, F.
    Kelemen, P.
    Koelsch, H.
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (04) : 467 - 472
  • [40] Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for treatment of atherosclerosis
    Masson, David
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (09) : 980 - 987